Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma ® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce
View HTML
Toggle Summary Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis
New Findings Presented at 2019 ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the potential for its Afirma ® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients
View HTML

Events

Date Event Details
Summary Toggle Jun 6, 2019 9:00 AM EDT
Jefferies 2019 Global Healthcare Conference
Summary Toggle Jun 5, 2019 2:00 PM CDT
The William Blair 39th Annual Growth Stock Conference

Presentations

Title Documents

Corporate Presentation June 2019